Physician

Richard Zekman, DO

According to 2025 Medicare claims, Richard Zekman, DO (NPI: 1043426521) practices medical oncology in the Detroit-Dearborn-Livonia, MI market, with the plurality of this provider's patient population coming from Wayne, MI. This provider's primary affiliated billing organization is MICHIGAN HEALTHCARE PROFESSIONALS PC (NPI: 1295023547; TIN: 451674932) and primary practice location at 48334-3292. Zekman is affiliated with the Honest ACO of Michigan LLC (ACO ID: D0236), participating under the REACH model.

Zekman's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 817 traditional Medicare patients, billed 253,043 HCPCS/CPT codes, and received $4,105,331 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,959 prescription claims across 497 beneficiaries totaling $6,698,219 in drug costs, led by Lenalidomide (Lenalidomide). DME data shows 58 claims. Open Payments data shows 6 records totaling $13,700. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,891,847 to $4,105,331. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,287,955 to $6,698,219. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $1,563 to $235.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	723	150,286	$1,891,847
2016	803	140,948	$1,903,901
2017	852	213,162	$2,640,623
2018	773	216,755	$3,251,244
2019	800	190,082	$3,118,555
2020	727	164,974	$2,376,975
2021	701	190,338	$3,656,829
2022	768	218,561	$2,685,930
2023	779	281,777	$3,459,670
2024	817	253,043	$4,105,331

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	257	1,552	$1,287,955
2016	307	1,878	$1,661,245
2017	330	1,963	$1,871,497
2018	327	2,107	$2,502,914
2019	348	2,259	$3,569,674
2020	365	2,431	$4,532,241
2021	348	2,406	$4,207,053
2022	414	2,269	$4,779,035
2023	449	2,572	$4,828,690
2024	497	2,959	$6,698,219

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	59	$12,255
2017	N/R	56	$4,180
2018	N/R	87	$4,132
2019	N/R	36	$3,831
2020	N/R	24	$1,621
2021	N/R	23	$2,982
2022	N/R	29	$1,177
2023	N/R	17	$7,629
2024	N/R	58	$1,105

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	308	563	$99
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	389	933	$68
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	164	514	$62
80047	Blood test, basic group of blood chemicals (calcium, ionized)	550	1,866	$13
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	550	2,145	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	88	2,198	$1,115,424
Revlimid	Lenalidomide	39	1,029	$717,576
Promacta	Eltrombopag Olamine	40	1,260	$707,330
Tagrisso	Osimertinib Mesylate	24	720	$410,545
Venclexta	Venetoclax	50	1,384	$389,975

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	17	$428
J8999	Prescription drug, oral, chemotherapeutic, nos	N	N/R	13	$351
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	28	$326

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	0	$0	N/R
Research Payments	Reported research-related payment or transfer-of-value amount.	6	$13,700	TRILLIUM THERAPEUTICS USA, LLC
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Richard Zekman, DO?

Tedicare shows public-source Medicare data for Richard Zekman, DO (NPI 1043426521), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Richard Zekman, DO have ACO affiliation data?

Richard Zekman, DO is shown with ACO affiliation data for Honest ACO of Michigan LLC (REACH, ACO ID D0236).

What billing organization is linked to Richard Zekman, DO?

Richard Zekman, DO is linked to MICHIGAN HEALTHCARE PROFESSIONALS PC (billing NPI 1295023547) in the available physician profile data.

Does Richard Zekman, DO have Open Payments data?

Richard Zekman, DO has 6 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.